Interim Report Q3 2018

Scandion Oncology A/S (”Scandion Oncology”) herby reports interim report for Q3 2018.

Third quarter (30-JUL-2018 – 30-SEP-2018) 

Net sales 0 (0)

Result after tax decreased to -1,013,567 (-422,162)

Result per share decreased to -0.14 (-0.06)

Equity ratio amounted to -0.84 (0.22)

Nine months (01-JAN-2018 – 30-SEP-2018)

Net sales 0 (0)

Result after tax decreased to -4,361,298 (-541,233)

Result per share decreased to -0.46 (-0.06)

Equity ratio amounted to -0.84 (0.22)

Highlights during Q3 2018

  • 05JUL18: The extraordinary shareholders' meeting resolved to elect Thomas Feldthus as new ordinary board member.
  • 05JUL18: The extraordinary general meeting resolved to raise up to SEK 26 million through an Initial Public Offering (“IPO”) at Spotlight Stock Market (“Spotlight”), Sweden.
  • 06AUG18: Scandion Oncology signs agreement with Sedermera Fondkommission regarding an IPO at Spotlight.
  • AUG18: Scandion Oncology hires Peter Michael Vestlev, MD as new Chief Medical Officer.
  • 06SEPT18: Scandion Oncology files a new patent application covering a new Mechanisms of Action of SCO-101 in inhibiting anti-cancer drug resistance.

Highlights after the balance sheet date

  • 01OCT18: Scandion Oncology is approved for listing at Spotlight.
  • 16OCT18: Scandion Oncology files a new patent application covering a second indication for SCO-101. The second indication is a non-cancer indication where there is a significant medical need and market potential.
  • 23OCT18: Through the new share issue, Scandion Oncology will receive approx. 1,500 new shareholders and SEK 26 million. Scandion Oncology’s new share issue was oversubscribed more than 4 times prior to the listing on Spotlight.
  • 08NOV18: Scandion Oncology has its first day of public trading at Spotlight.
  • 13NOV18: Scandion Oncology receives a small but important EU grant.
  • 16NOV18: Scandion Oncology receives an EU-Upstart grant.

For further information regarding Scandion Oncology, please contact:

Nils Brünner, CEO

Phone: +45 26 14 47 08


Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cell clones or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical animal studies, the company’s leading candidate drug, SCO-101, has been found to significantly enhance the efficacy of certain standard cancer treatments when given in combination. It has been shown in vitro-studies that SCO-101 restores chemotherapy sensitivity in resistant cells.

About Us

Scandion Oncology A/S is a clinical stage II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival and improved quality of life. The first-in-class lead candidate, SCO-101, is currently in clinical Phase II. The Company is targeting cancer drug resistance in various treatment modalities including, chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden. Ticker: SCOL.


Documents & Links